Foundayo is the first oral, small-molecule GLP-1 medication approved for weight loss. You take one pill daily with no food or water restrictions. Wegovy is an injectable GLP-1 that produces more weight loss on average (~15% vs. ~11%) and has cardiovascular outcome data, adolescent approval, and a longer track record. Both are FDA-approved, have similar side effect profiles, and work best when combined with diet and lifestyle changes. Your provider can help you decide which fits your goals and preferences.
Foundayo and Wegovy represent two different approaches to GLP-1-based weight loss treatment. One is a daily oral tablet, the other a weekly injection. Both are FDA-approved for chronic weight management as an adjunct to diet and exercise.
At PEAK Wellness & Aesthetics, we prescribe both. The right choice depends on your goals, your health history, your comfort with injections, and what your insurance covers. This guide breaks down the real differences so you can have an informed conversation with your provider.
How they work: oral small molecule vs. injectable peptide
Both medications target the same receptor — GLP-1 — but they’re built very differently.
Foundayo (orforglipron) is a small-molecule (non-peptide) GLP-1 receptor agonist. Unlike traditional GLP-1 medications that are large protein-based molecules requiring injection, orforglipron is a compact synthetic compound that can be absorbed through the gut. That’s what makes it an effective oral tablet — no injection needed.
Wegovy (semaglutide) is a peptide-based GLP-1 receptor agonist delivered as a once-weekly subcutaneous injection. It mimics the natural GLP-1 hormone, signaling your brain that you’re full, reducing appetite, and slowing digestion. Semaglutide has been studied extensively and has strong clinical data going back to 2021.
Both activate the GLP-1 receptor to reduce appetite and promote weight loss. The key difference is how they’re delivered and what that means for your daily routine.
Weight loss: what the studies show
Foundayo and Wegovy have not been compared head-to-head in a clinical trial, so we’re comparing results from separate studies with different patient populations. That said, the data gives us a reasonable picture of how the two medications compare.
Results from pivotal trials
| Outcome | Foundayo (17.2 mg) | Wegovy (2.4 mg) |
|---|---|---|
| Average weight loss | ~11% | ~15% |
| Average pounds lost | ~25 lbs | ~34 lbs |
| Achieved ≥10% loss | ~55% | ~69% |
| Trial duration | 72 weeks | 68 weeks |
| Trial name | ATTAIN-1 | STEP-1 |
Sources: ATTAIN-1 (2026) and STEP-1 (2021). These are separate trials, not a head-to-head comparison. Results are averages — individual responses vary.
Wegovy produces greater weight loss on average. However, Foundayo still delivers clinically meaningful results, and its convenience as an oral medication with no food or water restrictions may make it the better fit for some patients.
It’s also worth noting that the ATTAIN-1 trial tested higher investigational doses of orforglipron that are not included in the approved labeling. The data above reflects the highest approved dose (17.2 mg).
Side effects: similar GI profiles
Both medications cause similar gastrointestinal side effects. Nausea is the most common for both, especially early in treatment and during dose increases.
In the ATTAIN-1 trial, nausea occurred in approximately 35% of patients taking Foundayo at the approved dose. Other common side effects include diarrhea, constipation, and indigestion. The STEP-1 trial reported a similar GI side effect profile for Wegovy.
These side effects are usually mild to moderate and tend to improve as your body adjusts. Slow dose titration — which both medications use — helps minimize symptoms.
Both medications carry a boxed warning about thyroid C-cell tumors based on findings with other GLP-1 receptor agonists in rodents. Orforglipron (Foundayo) itself did not produce thyroid C-cell tumors in animal studies; the warning is a class-level precaution. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
The side effect profiles are similar. The biggest practical difference is how you take the medication — a daily pill vs. a weekly injection.
Dosing: daily oral tablet vs. weekly injection
This is where the two medications differ most in day-to-day experience.
| Feature | Foundayo (orforglipron) | Wegovy (semaglutide) |
|---|---|---|
| How it’s taken | Oral tablet, once daily | Subcutaneous injection, once weekly |
| Food restrictions | None — take any time of day | None (injection) |
| Dose steps | 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg | 0.25, 0.5, 1, 1.7, 2.4 mg |
| Maintenance dose | 17.2 mg daily | 2.4 mg weekly |
| Refrigeration | No | Yes (before first use) |
| Needle required | No | Yes (prefilled pen) |
Foundayo’s advantage is convenience. It’s a simple daily pill with no food or water restrictions, no refrigeration, and no needles. For patients who are uncomfortable with injections or who travel frequently, this can be a significant factor.
Wegovy’s advantage is dosing frequency. Once-weekly injections mean you only think about your medication one day per week. Some patients prefer that simplicity over remembering a daily pill.
It’s worth noting that Wegovy is also available as an oral tablet (Wegovy Pill), but that formulation has food and water restrictions — you must take it on an empty stomach with no more than 4 oz of water, then wait at least 30 minutes before eating or drinking. Foundayo has no such restrictions.
FDA approvals: established vs. new
Wegovy has a significant head start and broader set of FDA approvals.
Wegovy is approved for:
- Chronic weight management in adults (June 2021) as an adjunct to diet and exercise
- Adolescents ages 12+ with obesity
- Reducing cardiovascular risk (heart attack, stroke, cardiovascular death) in adults with established heart disease who have obesity or are overweight — based on the SELECT trial
- Treating MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver scarring
Foundayo is approved for:
- Chronic weight management in adults (April 2026) as an adjunct to diet and exercise
Wegovy’s cardiovascular outcome data from the SELECT trial is a meaningful differentiator. If you have established heart disease and are concerned about cardiovascular risk, Wegovy has evidence that Foundayo does not yet have. Foundayo is brand new, and additional clinical data may expand its indications over time.
Insurance coverage & cost
Wegovy has been on the market since 2021, and many insurance plans now cover it — though prior authorization is almost always required. Coverage depends on your specific plan, formulary, BMI, and weight-related health conditions.
Foundayo was just approved in April 2026, so insurance formulary coverage is still being established. It will take time for payers to add it to their formularies.
Self-pay and savings programs
Eli Lilly offers Foundayo through LillyDirect at $149–$299 per month for self-pay patients. A savings card is available for patients with commercial insurance, potentially reducing the cost to as low as $25 per month (subject to annual caps). These savings programs are not valid for patients with government insurance (Medicare, Medicaid, TRICARE).
Novo Nordisk offers savings programs for Wegovy as well. Pricing and eligibility change over time.
At PEAK, we check your insurance benefits before your first visit and help you understand which medication your plan is more likely to cover. If one is denied, we often try the other.
Related: Foundayo Savings Card: Eligibility & How to Apply • Foundayo (Orforglipron): What You Need to Know
How to choose: a decision framework
- You prefer a daily oral tablet over injections
- You want no food or water restrictions with your medication
- You travel frequently and want a medication that doesn’t require refrigeration or needles
- Your insurance covers Foundayo or the self-pay cost works for your budget
- You’ve had difficulty tolerating injectable GLP-1 medications
- Maximum weight loss is your primary goal
- You have established cardiovascular disease and want proven CV risk reduction
- You’re an adolescent (12–17) with obesity
- You have MASH (fatty liver disease with scarring)
- You prefer once-weekly dosing over a daily pill
- Your insurance covers Wegovy
Both medications are effective, and the “best” choice depends on your individual situation. Some patients prioritize convenience and prefer an oral option. Others prioritize maximum weight loss or need the cardiovascular benefits that Wegovy offers. For more guidance, see our article on how to choose a weight loss medication.
What if I start one and it doesn’t work?
Switching from Wegovy to Foundayo (or vice versa) is safe when done under medical supervision. Your dose may need to be adjusted during the transition.
We see patients who want to switch for a variety of reasons: they prefer the convenience of an oral medication, they’ve plateaued on one medication and want to try another, they’re having side effects they can’t tolerate, or their insurance coverage has changed.
This is one reason working with a medical weight loss team matters. We can adjust your treatment plan based on how you’re actually responding — not just write a prescription and hope for the best.
Can I take both together?
No. You should not take Foundayo and Wegovy at the same time. They both activate the GLP-1 receptor, and combining them would increase side effects without additional benefit. You take one or the other.
